While Everyone Was Selling, I Initiated a New Position in This Mid-Cap Biotech
I made exactly one trade Friday — and I went to Denmark to do it.
I’m Eyeing 2 Biopharma Stocks While Everyone Else Gawks at Big Tech
Here are a couple of oncology names that are steadily moving up.
A Low-Priced Biotech Is Back in the Bargain Bin – And I’m Adding
This beaten-down small-cap offers rich options premiums, and an attractive setup.
As China Summit Steals Headlines, I Am Eyeing These Three Stocks
This is how I’m trading 3 names as I navigate a choppy market amid U.S.-China meeting.